Clinical trial
Phase II Study of Imatinib Mesylate in Chordoma
NCT00150072 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Imatinib Mesylate in Chordoma
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2004
- Completion date
- April 30, 2008
- Enrollment
- 55 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.